RxDoctor Payments Data

Paul Worrell, DO

Family Medicine · Dallas, TXNPI 1720195779

Payments from drug & device makers

$26,774in general payments, 2019–2025

Across 1,734 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Amgen$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$26,762100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)230$3,044
AstraZeneca125$2,651
Novo Nordisk196$2,355
Amgen(2 entities)105$1,873
GSK99$1,493
Lilly USA, LLC103$1,256
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC88$1,023
Pfizer69$1,005
Boehringer Ingelheim58$772
Esperion Therapeutics, Inc.45$724
Johnson & Johnson45$713
Bayer42$571
Corcept Therapeutics27$545
Merck44$539
Arbor Pharmaceuticals, Inc.38$509
Amarin Pharma, Inc.25$507
Otsuka America Pharmaceutical, Inc.26$504
Abbott21$377
Sanofi-aventis U.S. LLC22$376
Radius Health, Inc.13$290
Kowa Pharmaceuticals America, Inc.20$290
Eisai Inc.23$279
Lundbeck LLC11$237
Novartis12$222
Biohaven Pharmaceuticals, Inc.12$217
Dexcom, Inc.10$211
Astellas Pharma US Inc11$208
Biohaven Pharmaceutical Holding Company Ltd.10$200
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$193
Scilex Pharmaceuticals Inc.13$180
Axsome Therapeutics, Inc.7$177
Genentech USA, Inc.9$163
Ironwood Pharmaceuticals, Inc10$163
Teva Pharmaceuticals USA, Inc.9$154
Bausch Health US, LLC10$154
Antares Pharma, Inc.8$153
Collegium Pharmaceutical, Inc.4$150
Cerapedics Inc.1$141
Medtronic4$135
Corium, LLC5$125
Exact Sciences7$123
Noven Therapeutics, LLC6$114
Aytu Biopharma, Inc.5$103
Jazz Pharmaceuticals Inc.5$101
Supernus Pharmaceuticals, Inc.5$94
Paratek Pharmaceuticals, Inc.6$93
Idorsia Pharmaceuticals US Inc5$78
Upsher-smith Laboratories LLC4$69
Azurity Pharmaceuticals, Inc.4$68
Optinose US, Inc.4$68
Avanir Pharmaceuticals, Inc.4$67
Assertio Therapeutics, Inc.4$66
Sunovion Pharmaceuticals Inc.5$62
Adlon Therapeutics L.p.5$62
Avvisto Therapeutics, LLC3$58
Takeda Pharmaceuticals U.S.A., Inc.5$49
Ironshore Pharmaceuticals Inc.3$48
Currax Pharmaceuticals LLC4$48
Nalpropion Pharmaceuticals LLC3$42
Viiv Healthcare Company2$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,774 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$99,279
Medicare patients
202
Services billed
1,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$105,998
FarxigaDapagliflozin Propanediol72$76,762
OzempicSemaglutide61$66,312
JardianceEmpagliflozin42$53,455
RybelsusSemaglutide11$23,279
EliquisApixaban23$22,669
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$21,324
XareltoRivaroxaban20$19,316
EntrestoSacubitril/Valsartan14$16,587
Soliqua 100-33Insulin Glargine/Lixisenatide22$15,453
TrulicityDulaglutide11$14,401
LinzessLinaclotide12$13,518
RestasisCyclosporine13$7,801
Potassium Chloride117$3,946
Rosuvastatin Calcium315$3,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,256$120,399114 claims
Novo NordiskOzempic, Rybelsus$2,355$89,59172 claims
AstraZenecaFarxiga$2,651$76,76272 claims
Boehringer IngelheimJardiance$772$53,45542 claims
PfizerEliquis$1,005$22,66923 claims
AbbVieLinzess, Restasis, Synthroid$3,044$22,37540 claims
GSKTrelegy Ellipta$1,493$21,32414 claims
Johnson & JohnsonXarelto$713$19,31620 claims
NovartisEntresto$222$16,58714 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$376$15,45322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →